Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Next Previous
Trial Profile

An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms EVOKE-02
  • Sponsors Gilead Sciences

Most Recent Events

  • 30 Apr 2025 Results evaluating efficacy of Sacituzumab-govitecan presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 05 Sep 2024 According to Gilead Sciences Media Release, data from EVOKE-02 supports the ongoing Phase 3 EVOKE-03 study.
  • 05 Sep 2024 According to a Gilead Sciences media release, results to be presented from Cohorts C (non-squamous) and D (squamous) of the Phase 2 EVOKE-02 study of Trodelvy in previously untreated mNSCLC in combination with pembrolizumab and carboplatin during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top